Evidence map›Paper›PMID 30065027›Full record

ArticleScience signaling2018

Caught in the "Akt": Cross-talk between EphA2 and EGFR through the Akt-PIKfyve axis maintains cellular sensitivity to EGF.

Xiaojun Shi, Bingcheng Wang

Open access · greenAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Science signaling, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Xiaojun ShiRammelkamp Center for Research and Department of Medicine, MetroHealth Campus; and Departments of Pharmacology, Oncology, Physiology and Biophysics, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, 2500 MetroHealth Drive, Cleveland, OH 44109, USA.ORCID 0000-0002-8060-5880
Bingcheng WangRammelkamp Center for Research and Department of Medicine, MetroHealth Campus; and Departments of Pharmacology, Oncology, Physiology and Biophysics, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, 2500 MetroHealth Drive, Cleveland, OH 44109, USA. bxw14@case.edu.
MetroHealth · US

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARK R CHANCE · 1987 to 2026
$142.3M
Targeting EphA2 in GlioblastomaR01NS096956 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI WANG, BINGCHENG · 2016 to 2021
$2.6M
EphA2 kinase in prostate cancerR01CA155676 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI WANG, BINGCHENG · 2011 to 2016
$1.6M
Akt-EphA2 Crosstalk in Glioma InvasionR01CA152371 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MIAO, HUI, WANG, BINGCHENG · 2010 to 2014
$1.6M
NCI NIH HHS P30 CA043703NCI NIH HHS R01 CA152371NCI NIH HHS R01 CA155676NINDS NIH HHS R01 NS096956
6 · The paper itself

Abstract

Activation of EGFR (epidermal growth factor receptor) and Eph receptor often exerts opposing effects on cell functions. In this issue of

Indexed as

Epidermal Growth FactorErbB ReceptorsCell MovementProto-Oncogene Proteins c-aktSignal TransductionEpidermal Growth FactorErbB ReceptorsProto-Oncogene Proteins c-akt

Identifiers

PMID30065027
PMCPMC6311088
OpenAlexW2887664324

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.